Fig. 1: Drug combination screen identifies GSK-J1 acting synergistically with TCP. | British Journal of Cancer

Fig. 1: Drug combination screen identifies GSK-J1 acting synergistically with TCP.

From: Therapeutically targeting head and neck squamous cell carcinoma through synergistic inhibition of LSD1 and JMJD3 by TCP and GSK-J1

Fig. 1

a The workflow of drug combination screen. IC50, median inhibitory concentration. CI, combination index. b Eight compounds targeting five classes of epigenetic modulators were examined in a combination screen with TCP in FaDu cells. The CI quantitatively depicts synergism (CI < 1), additive effect (CI = 1) and antagonism (CI > 1). c, d Sensitivity of FaDu, Cal27 to TCP alone, GSK-J1 alone or TCP combined with GSK-J1. Survival fraction (left) and the CI (right) are shown for each of these two cell lines. Fa, fraction affected. Error bars represent means ± SD. e, f Crystal violet staining of anchorage-dependent colony formation assay indicates the sensitivity of cells to control (DMSO), TCP, GSK-J1 or TCP combined with GSK-J1. Effect of treatments is shown for FaDu and Cal27 cells.

Back to article page